ArticleBioactive materials2026
Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering immunosuppressive niches by spatial single-cell proteomics: spatial interaction networks and translational opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.